Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme
Abstract Background Accumulating evidence demonstrates the oncogenic roles of lncRNA (long non-coding RNA) molecules in a wide variety of cancer types including glioma. Equally important, However, tumorigenic functions of lncRNA in glioma remain largely unclear. A recent study suggested lncRNA SNHG1...
Main Authors: | Zhenzhe Li, Jixing Zhang, Hongshan Zheng, Chenlong Li, Jinsheng Xiong, Weiliang Wang, Hongbo Bao, Hua Jin, Peng Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1371-0 |
Similar Items
-
DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma
by: Chenfei Lu, et al.
Published: (2020-02-01) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01) -
The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01) -
Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)